Literature DB >> 29688496

ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus.

Bing Yang1, Alison Schaefer2, Ying-Ying Wang3, Justin McCallen2, Phoebe Lee2, Jay M Newby4, Harendra Arora5, Priya A Kumar5, Larry Zeitlin6, Kevin J Whaley6, Scott A McKinley7, William A Fischer8, Dimple Harit1, Samuel K Lai1,2,9.   

Abstract

Filoviruses, including Ebola, have the potential to be transmitted via virus-laden droplets deposited onto mucus membranes. Protecting against such emerging pathogens will require understanding how they may transmit at mucosal surfaces and developing strategies to reinforce the airway mucus barrier. Here, we prepared Ebola pseudovirus (with Zaire strain glycoproteins) and used high-resolution multiple-particle tracking to track the motions of hundreds of individual pseudoviruses in fresh and undiluted human airway mucus isolated from extubated endotracheal tubes. We found that Ebola pseudovirus readily penetrates human airway mucus. Addition of ZMapp, a cocktail of Ebola-binding immunoglobulin G antibodies, effectively reduced mobility of Ebola pseudovirus in the same mucus secretions. Topical delivery of ZMapp to the mouse airways also facilitated rapid elimination of Ebola pseudovirus. Our work demonstrates that antibodies can immobilize virions in airway mucus and reduce access to the airway epithelium, highlighting topical delivery of pathogen-specific antibodies to the lungs as a potential prophylactic or therapeutic approach against emerging viruses or biowarfare agents.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29688496      PMCID: PMC6093450          DOI: 10.1093/infdis/jiy230

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

Review 1.  Protein stability in pulmonary drug delivery via nebulization.

Authors:  Sebastian P Hertel; Gerhard Winter; Wolfgang Friess
Journal:  Adv Drug Deliv Rev       Date:  2014-10-12       Impact factor: 15.470

Review 2.  Nebulization as a delivery method for mAbs in respiratory diseases.

Authors:  Renaud Respaud; Laurent Vecellio; Patrice Diot; Nathalie Heuzé-Vourc'h
Journal:  Expert Opin Drug Deliv       Date:  2015-01-05       Impact factor: 6.648

3.  Health-care worker mortality and the legacy of the Ebola epidemic.

Authors:  David K Evans; Markus Goldstein; Anna Popova
Journal:  Lancet Glob Health       Date:  2015-07-09       Impact factor: 26.763

4.  Infectious Disease. Genomes reveal start of Ebola outbreak.

Authors:  Gretchen Vogel
Journal:  Science       Date:  2014-08-29       Impact factor: 47.728

5.  Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology.

Authors:  Douglas S Reed; Matthew G Lackemeyer; Nicole L Garza; Lawrence J Sullivan; Donald K Nichols
Journal:  Microbes Infect       Date:  2011-05-25       Impact factor: 2.700

6.  Nanoparticle diffusion in respiratory mucus from humans without lung disease.

Authors:  Benjamin S Schuster; Jung Soo Suk; Graeme F Woodworth; Justin Hanes
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

Review 7.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

8.  Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs.

Authors:  Christopher W Seibert; Saad Rahmat; Jens C Krause; Dirk Eggink; Randy A Albrecht; Peter H Goff; Florian Krammer; J Andrew Duty; Nicole M Bouvier; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

9.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

10.  Transmission of Ebola virus from pigs to non-human primates.

Authors:  Hana M Weingartl; Carissa Embury-Hyatt; Charles Nfon; Anders Leung; Greg Smith; Gary Kobinger
Journal:  Sci Rep       Date:  2012-11-15       Impact factor: 4.379

View more
  11 in total

1.  An intranasally administered monoclonal antibody cocktail abrogates ricin toxin-induced pulmonary tissue damage and inflammation.

Authors:  Yinghui Rong; Fernando J Torres-Velez; Dylan Ehrbar; Jennifer Doering; Renjie Song; Nicholas J Mantis
Journal:  Hum Vaccin Immunother       Date:  2019-10-29       Impact factor: 3.452

Review 2.  Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections.

Authors:  Hilal Ahmad Parray; Shivangi Shukla; Reshma Perween; Ritika Khatri; Tripti Shrivastava; Vanshika Singh; Praveenkumar Murugavelu; Shubbir Ahmed; Sweety Samal; Chandresh Sharma; Subrata Sinha; Kalpana Luthra; Rajesh Kumar
Journal:  Appl Microbiol Biotechnol       Date:  2021-08-23       Impact factor: 5.560

3.  Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin.

Authors:  Chad J Roy; Greta Van Slyke; Dylan Ehrbar; Zachary A Bornholdt; Miles B Brennan; Lioudmila Campbell; Michelle Chen; Do Kim; Neil Mlakar; Kevin J Whaley; Jeffrey W Froude; Fernando J Torres-Velez; Ellen Vitetta; Peter J Didier; Lara Doyle-Meyers; Larry Zeitlin; Nicholas J Mantis
Journal:  NPJ Vaccines       Date:  2020-02-13       Impact factor: 7.344

Review 4.  Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.

Authors:  Yara Al Ojaimi; Timothée Blin; Juliette Lamamy; Matthieu Gracia; Aubin Pitiot; Caroline Denevault-Sabourin; Nicolas Joubert; Jean-Pierre Pouget; Valérie Gouilleux-Gruart; Nathalie Heuzé-Vourc'h; Débora Lanznaster; Sophie Poty; Thomas Sécher
Journal:  Pharmacol Ther       Date:  2021-10-20       Impact factor: 13.400

Review 5.  The biophysical principles underpinning muco-trapping functions of antibodies.

Authors:  Alison Schaefer; Samuel K Lai
Journal:  Hum Vaccin Immunother       Date:  2021-07-27       Impact factor: 4.526

6.  Antibody-mediated trapping in biological hydrogels is governed by sugar-sugar hydrogen bonds.

Authors:  Jennifer L Schiller; Mary M Fogle; Olivia Bussey; William J Kissner; David B Hill; Samuel K Lai
Journal:  Acta Biomater       Date:  2020-03-05       Impact factor: 8.947

Review 7.  Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing.

Authors:  Kevin J Whaley; Larry Zeitlin
Journal:  Hum Vaccin Immunother       Date:  2021-07-14       Impact factor: 4.526

Review 8.  Engineering monoclonal antibody-based contraception and multipurpose prevention technologies†.

Authors:  Deborah J Anderson; Joseph A Politch; Richard A Cone; Larry Zeitlin; Samuel K Lai; Philip J Santangelo; Thomas R Moench; Kevin J Whaley
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.161

9.  A Humanized Monoclonal Antibody Cocktail to Prevent Pulmonary Ricin Intoxication.

Authors:  Yinghui Rong; Michael Pauly; Adrian Guthals; Henry Pham; Dylan Ehrbar; Larry Zeitlin; Nicholas J Mantis
Journal:  Toxins (Basel)       Date:  2020-03-29       Impact factor: 4.546

Review 10.  Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.

Authors:  Carlos Cruz-Teran; Karthik Tiruthani; Morgan McSweeney; Alice Ma; Raymond Pickles; Samuel K Lai
Journal:  Adv Drug Deliv Rev       Date:  2020-12-09       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.